Completed PHASE3 INTERVENTIONAL NCT00393471

Study Comparing Etanercept Plus Methotrexate to Either Etanercept or Methotrexate Alone in Rheumatoid Arthritis.

A Double-blind Study Evaluating the Efficacy and Safety of the Combination of Etanercept and Methotrexate in Comparison to Etanercept Alone or Methotrexate Alone in Rheumatoid Arthritis Patients.

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer

Conditions Active Rheumatoid Arthritis

Interventions Etanercept

Updated 6 times since 2017 Last updated: Dec 12, 2023 Started: Oct 31, 2000 Completion: Oct 31, 2001

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Active Rheumatoid Arthritis and is currently completed. Wyeth is now a wholly owned subsidiary of Pfizer leads this study, which shows 6 recorded versions since 2000 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2024 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — Jan 2024 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jan 2021 [monthly]

Completed PHASE3

First recorded

Oct 2000

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Wyeth is now a wholly owned subsidiary of Pfizer

Data source: Wyeth is now a wholly owned subsidiary of Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Adelaide, Australia , Alkmaar, Netherlands , Arnhem, Netherlands , Athens, Greece , Barcelona, Spain , Berlin, Germany , Bordeaux, France , Brest, France , Brussels, Belgium , Bucharest, Romania and 72 more locations